Indication
Malignant melanoma with BRAF V600 mutation
Malignant melanoma with BRAF V600 mutation is an aggressive neoplasm of the integumentary system arising from the oncogenic transformation of melanocytes, predominantly located in the skin. Read more about Malignant melanoma with BRAF V600 mutation
2 drugs 1 manufacturers
Drugs that treat it
Common Malignant melanoma with BRAF V600 mutation therapies.
TECENTRIQ HYBREZA (atezolizumab-hyaluronidase-tqjs)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMalignant melanoma with BRAF V600 mutation is an aggressive neoplasm of the integumentary system arising from the oncogenic transformation of melanocytes, predominantly located in the skin.
This clinical state is defined by somatic activating mutations at codon 600 of the *BRAF* oncogene—most frequently BRAF V600E or V600K—which occur in approximately 40% to 50% of cutaneous melanomas.
Pathophysiologically, these alterations cause constitutive kinase activation of the intracellular mitogen-activated protein kinase (MAPK/ERK) signaling cascade.
This continuous signaling drives unchecked cellular proliferation, evasion of apoptosis, increased invasiveness, and high metastatic potential, characterizing a distinct molecular subtype targeted by specific kinase inhibitor regimens.
- medicalnewstoday.com
Malignant melanoma with BRAF V600 mutation is an aggressive neoplasm of the integumentary system arising from the oncogenic transformation of melanocytes, predominantly located in the skin
- nih.gov
Malignant melanoma with BRAF V600 mutation is an aggressive neoplasm of the integumentary system arising from the oncogenic transformation of melanocytes, predominantly located in the skin Pathophysiologically, these alterations cause constitutive kinase activation of the intracellular mitogen-activated protein kinase (MAPK/ERK) signaling cascade This continuous signaling drives unchecked cellular proliferation, evasion of apoptosis, increased invasiveness, and high metastatic potential, charact...
- hopkinsmedicine.org
This clinical state is defined by somatic activating mutations at codon 600 of the *BRAF* oncogene—most frequently BRAF V600E or V600K—which occur in approximately 40% to 50% of cutaneous melanomas
- cityofhope.org
This clinical state is defined by somatic activating mutations at codon 600 of the *BRAF* oncogene—most frequently BRAF V600E or V600K—which occur in approximately 40% to 50% of cutaneous melanomas
- incytediagnostics.com
This clinical state is defined by somatic activating mutations at codon 600 of the *BRAF* oncogene—most frequently BRAF V600E or V600K—which occur in approximately 40% to 50% of cutaneous melanomas
- esmo.org
Pathophysiologically, these alterations cause constitutive kinase activation of the intracellular mitogen-activated protein kinase (MAPK/ERK) signaling cascade This continuous signaling drives unchecked cellular proliferation, evasion of apoptosis, increased invasiveness, and high metastatic potential, characterizing a distinct molecular subtype targeted by specific kinase inhibitor regimens
- cancer.gov
This continuous signaling drives unchecked cellular proliferation, evasion of apoptosis, increased invasiveness, and high metastatic potential, characterizing a distinct molecular subtype targeted by specific kinase inhibitor regimens
Personalize your experience
Follow Malignant melanoma with BRAF V600 mutation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.